The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer
dc.Affiliation | October University for modern sciences and Arts MSA | |
dc.contributor.author | Mohamed S. Othman, | |
dc.contributor.author | Mohamed Tharwat Elabbasy, | |
dc.contributor.author | Ahmed M. Aref, | |
dc.contributor.author | Aya A. Altaleb | |
dc.contributor.author | Marwa Hamdy Mohammed, | |
dc.contributor.author | Doaa Atef Mohamed Soliman, | |
dc.contributor.author | Nashwa El-Khazragy, | |
dc.date.accessioned | 2024-11-06T13:16:37Z | |
dc.date.available | 2024-11-06T13:16:37Z | |
dc.date.issued | 2023-10 | |
dc.description | miRNA, micro-RNA; HER2-MBC, HER2-positive Metastatic Breast cancer; BC, breast cancer; BL, baseline; 1C, after completing Trastuzumab treatment; FOXP3, forkhead box P3; HER2, human epidermal growth factor receptor 2; TTP, time to progression; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology; PASS, Power Analysis and Sample Size Software; ROC, Receiving operating characteristics curve; CI, 95% confidence interval; AUC, area under the curve. | |
dc.description.abstract | Purpose: Resistance to Trastuzumab is a significant challenge in the management of HER2-positive Metastatic Breast cancer (HER2-MBC), and a better understanding of the molecular causes of resistance is required to develop more effective treatment plans. While elevated plasma levels of miR-200 and FOXP3 have been linked to breast cancer progression and treatment response, no clinical studies have confirmed these results. Methods: The study involved 40 patients with HER2-positive metastatic breast cancer (HER2-MBC). The expression levels of miR-200c-3p and the FOXP3 gene were assessed in plasma samples at two time points: baseline (BL) and after the consent completion of one cycle of Trastuzumab, utilizing quantitative polymerase chain reaction (qPCR). Clinical response to Trastuzumab was evaluated 12 months post-therapy and correlated with the time to progression (TTP) through Kaplan-Meier analysis. Results: Low plasma expression level of miR-200c-3p was detected before therapy in HER2-MBC, compared to healthy controls, and decreased dramatically in the follow-up sample at disease progression, while increased after one cycle of Trastuzumab therapy in patients who were sensitive to Trastuzumab. At baseline, a low expression level of miR-200c was significantly associated with overexpression of FOXP3, poor prognosis, and shorter time to progression. Conclusions: The findings suggest that miR-200c-3p may be a promising biomarker for predicting the response to Trastuzumab in HER2-MBC patients. | |
dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=13158&tip=sid&clean=0 | |
dc.identifier.doi | DOI: 10.1177/15330338241292226 | |
dc.identifier.uri | https://repository.msa.edu.eg/handle/123456789/6189 | |
dc.language.iso | en | |
dc.publisher | Sage: Technology in Cancer Research & Treatment | |
dc.relation.ispartofseries | 2 Technology in Cancer Research & Treatment; Volume 23: 1-10 | |
dc.subject | Trastuzumab | |
dc.subject | HER2-positive breast cancer | |
dc.subject | metastatic breast cancer | |
dc.subject | drug resistance | |
dc.subject | miR-200c | |
dc.subject | FOXP3 | |
dc.subject | predictor biomarker | |
dc.title | The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer | |
dc.type | Article |